Cerebral toxoplasmosis in the twenty-first century: long-term clinical outcomes in a retrospective cohort study in the Netherlands.

IF 3.1 2区医学 Q3 IMMUNOLOGY

AIDS Pub Date : 2025-09-23 DOI:10.1097/QAD.0000000000004356

C M van Deuzen, B J A Rijnders, H I Bax, C Rokx, T E M S de Vries-Sluijs, C A M Schurink, J L Nouwen, M de Mendonça-Melo, A A Anas, E van Gorp, L Slobbe, J J van Hellemond, E van Nood

{"title":"Cerebral toxoplasmosis in the twenty-first century: long-term clinical outcomes in a retrospective cohort study in the Netherlands.","authors":"C M van Deuzen, B J A Rijnders, H I Bax, C Rokx, T E M S de Vries-Sluijs, C A M Schurink, J L Nouwen, M de Mendonça-Melo, A A Anas, E van Gorp, L Slobbe, J J van Hellemond, E van Nood","doi":"10.1097/QAD.0000000000004356","DOIUrl":null,"url":null,"abstract":"Background: Cerebral toxoplasmosis is a common opportunistic infection in people with HIV (PWH), associated with high morbidity and mortality. It is unclear how clinical characteristics, treatment response and long-term clinical outcomes in PWH with cerebral toxoplasmosis have changed due to improved treatment of HIV.Methods: This single-centre retrospective observational cohort study of PWH with cerebral toxoplasmosis included patients over almost 25 years.Results: 63 eligible patients were identified. Most patients were late presenters presenting with headache and neurological symptoms. Overall survival was 79% over a mean follow up of 15 years. 73% of deaths occurred within the first year after diagnosis. Almost 10% of patients experienced residual impairments.Conclusions: An earlier diagnosis of HIV reduces the incidence of cerebral toxoplasmosis due to timely initiation of cART and anti-Toxoplasma prophylaxis. High index of suspicion by clinicians is vital to timely start anti-Toxoplasma therapy. If treated correctly and timely, overall survival is high.","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAD.0000000000004356","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cerebral toxoplasmosis is a common opportunistic infection in people with HIV (PWH), associated with high morbidity and mortality. It is unclear how clinical characteristics, treatment response and long-term clinical outcomes in PWH with cerebral toxoplasmosis have changed due to improved treatment of HIV.

Methods: This single-centre retrospective observational cohort study of PWH with cerebral toxoplasmosis included patients over almost 25 years.

Results: 63 eligible patients were identified. Most patients were late presenters presenting with headache and neurological symptoms. Overall survival was 79% over a mean follow up of 15 years. 73% of deaths occurred within the first year after diagnosis. Almost 10% of patients experienced residual impairments.

Conclusions: An earlier diagnosis of HIV reduces the incidence of cerebral toxoplasmosis due to timely initiation of cART and anti-Toxoplasma prophylaxis. High index of suspicion by clinicians is vital to timely start anti-Toxoplasma therapy. If treated correctly and timely, overall survival is high.

查看原文本刊更多论文

21世纪脑弓形体病：荷兰一项回顾性队列研究的长期临床结果

背景：脑弓形虫病是HIV感染者（PWH）中一种常见的机会性感染，具有较高的发病率和死亡率。目前尚不清楚HIV治疗的改善如何改变PWH脑弓形体病的临床特征、治疗反应和长期临床结局。方法：这项单中心回顾性观察队列研究纳入了近25岁的PWH伴脑弓形虫病患者。结果：筛选出63例符合条件的患者。大多数患者以头痛和神经系统症状为主。在平均15年的随访中，总生存率为79%。73%的死亡发生在诊断后的第一年。几乎10%的患者出现了残留损伤。结论：早期诊断HIV可通过及时启动cART和抗弓形虫预防降低脑弓形虫病的发病率。临床医生的高怀疑指数对于及时开始抗弓形虫治疗至关重要。如果治疗正确及时，总生存率很高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

AIDS 医学-病毒学

CiteScore

5.90

自引率

5.30%

发文量

478

审稿时长

3 months

期刊介绍： Publishing the very latest ground breaking research on HIV and AIDS. Read by all the top clinicians and researchers, AIDS has the highest impact of all AIDS-related journals. With 18 issues per year, AIDS guarantees the authoritative presentation of significant advances. The Editors, themselves noted international experts who know the demands of your work, are committed to making AIDS the most distinguished and innovative journal in the field. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.